Ferring is a speciality, research-driven biopharmaceutical company that identifies, develops, manufactures and markets innovative products in the fields of reproductive health, urology, gastroenterology and endocrinology.
From its origins as a distinctly Scandinavian company, Ferring has developed into a global business with operating units in most important pharmaceutical markets around the world.
Ferring (Pty) Ltd established operations in South Africa in 1996 with a limited portfolio of products. The company has now expanded its activities into a number of other countries within the region including Namibia, Botswana, Kenya and Mauritius. The portfolio of products has grown to include a range of products in the fields of urology, gastroenterology, obstetrics, gynaecology and infertility treatment.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
Ferring's vision is to be the partner of choice for patients, physicians and business associates offering a leading portfolio of products and services in its key therapeutic areas, using innovative methodologies to provide tailored treatments that function on the body's own terms.